Synthetic Genetic Codes Move Closer to Programmable Biology
Synthetic genetic codes are moving closer to programmable biology as automated cell-free systems enable faster testing of new protein chemistries in R&D.
Could Roche’s Molecular Glue Deal Signal a New Drug Discovery Race?
Drug discovery in molecular glues gains momentum as Roche partners with Chinese company, Defand Therapeutics.
How Sensor-Enhanced Patient Data Completes the Story of the Trial
How much can clinical trials miss when researchers rely solely on patient-reported outcomes? Dr Helen Brooker, Director of Product and Clinical Data at Signant Health, joins Trisha Pillay to discuss how wearable sensors complement electronic clinical outcome assessments (eCOA).
Integrated Pharma Operations and Supply Chain Management
Pharma operations and supply chain management are converging with forecasting, manufacturing, resilience, and digitalisation of Technical Operations.
FDA’s AEMS Updated for Consolidated Adverse Event Monitoring
The FDA’s AEMS platform consolidates adverse event reporting beyond just integrating FAERS. Explore its impact on safety signals and pharmacovigilance.
FDA MedWatch: Adverse Event Reporting at the Centre of Drug Safety
The FDA’s MedWatch supports drug and device safety through voluntary reports, mandatory industry submissions, and safety alerts. Explore its role in MedSafety Week 2026.